| Document |
Document Title |
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2020/005807A1 |
Provided herein are compounds of Formula (I´) or (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Al...
|
|
WO/2020/006294A1 |
Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.
|
|
WO/2019/246109A1 |
Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions.
|
|
WO/2019/243179A1 |
The present invention relates to disubstituted 5(3)-pyrazole carboxylates of the formula (la) or (lb) and a process for their preparation wherein R1, R2, R3, R4 and n are defined as above.
|
|
WO/2019/243999A1 |
The present invention comprises compounds of Formula (I). wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-y-t mediated syndrome, disorde...
|
|
WO/2019/243178A1 |
The present invention relates to disubstituted 3-pyrazole carboxylates of the formula (I) and a process for their preparation (I) wherein R1, R2, R3, R4 and n are defined as above.
|
|
WO/2019/241796A1 |
Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein m...
|
|
WO/2019/241311A1 |
Selective small molecule regulators of GIRK potassium channels are provided, which are effective in treatment of post-traumatic stress disorder and other medical conditions.
|
|
WO/2019/234740A1 |
Provided are compounds that act as covalent inhibitors of mitogen-activated protein kinase kinase 7 (MKK7 enzyme), method of preparation and uses thereof.
|
|
WO/2019/230831A1 |
This method comprises steps: (i) reacting a compound represented by formula (A) with hydrazine to produce a compound represented by formula (B); (ii) reacting the compound represented by formula (B) with formaldehyde to produce a compoun...
|
|
WO/2019/229464A1 |
There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depressi...
|
|
WO/2019/224138A1 |
The invention relates to a method for producing compounds of formula (I), (I), based on compounds of formula (II), (II), wherein R1, R2 and R3 have the above meaning and wherein R1 and R3 do not simultaneously represent hydrogen in a com...
|
|
WO/2019/223186A1 |
The invention relates to the technical field of co-crystal pesticides, and in particular relates to a triazole sulcotrione-salicylic acid co-crystal, a preparation method thereof, and an application thereof. The triazole sulcotrione-sali...
|
|
WO/2019/225552A1 |
The present invention provides salts of (E)-N-methyl-4-((2-(4-((E)-4,4,4-trifluoro-1-(3-fluoro-1H-in
dazol-5-yl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)amino)but-2-
enamide represented by the formula I and acids, and crystals thereof, posse...
|
|
WO/2019/224139A1 |
The present invention relates to a method for producing compounds of the formula (I), by halogenation of compounds of formula (II), wherein R1, R2, R3 and X are defined according to the invention.
|
|
WO/2019/222912A1 |
Disclosed is a class of pyrazole derivatives as shown in general formula stru-1, with each substituent defined in detail in the description. The pyrazole derivatives disclosed in the present invention are suitable for preventing and cont...
|
|
WO/2019/226936A1 |
4-Hydroxyphenyl-2H-indazol-5-ol compounds are estrogen receptor beta ligands that have immunomodulatory properties and increase oligodendrocyte survival, differentiation, and remyelination. The compounds, compositions, and kits are usefu...
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
|
WO/2019/224677A1 |
The present invention relates to a method for the production of substituted heterocyclic compounds of Formula (I) or of salts thereof.
|
|
WO/2019/226643A1 |
Described herein are methods and compositions for treating a spinal injury. Aspects of the invention relate to administering to a subject an agent that upmodulates KCC2. Another aspect of the invention relates to administering to a subje...
|
|
WO/2019/218024A1 |
The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compoun...
|
|
WO/2019/220962A1 |
The present invention provides: a method for producing a 3-difluoromethylpyrazole compound or a 3-difluoromethylalkylpyrazole-4-carboxylic acid compound, which comprises a step wherein a difluoroacetyl group-containing compound, a hydraz...
|
|
WO/2019/215427A1 |
A process for forming a carbon-carbon bond to couple an aryl or heteroaryl group of a first compound with an alkyl or cycloalkyl moietyof a second compound, the process comprising reacting the first compound with the second compound in t...
|
|
WO/2019/213335A1 |
The invention generally relates to orally bioavailable prodrugs of Edaravone (including analogs, derivatives, and salts thereof) with altered pharmacokinetic properties and methods of use thereof.
|
|
WO/2019/206155A1 |
The present invention provides an EZH2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of the EZH2 inhibitor. Specifically, the present invention provides N-((4,6-dimethyl-2-oxo-1,2-dih...
|
|
WO/2019/210266A1 |
Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).
|
|
WO/2019/205021A1 |
Provided is an amorphous teneligliptin 2.5 hydrobromide and a preparation method thereof. The method includes: rotary evaporation of a teneligliptin 2.5 hydrobromide hydrate under a certain water bath temperature by using a rotary evapor...
|
|
WO/2019/206871A1 |
The present invention relates to a sodium salt of N-((1,2,3,5,6,7-hexahydro-s-indacen- 4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide and to hydrates, solvates and polymorphic forms thereof. The present invention further relates t...
|
|
WO/2019/201296A1 |
The invention relates to a pyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and specifically to said compound of formula (I-1), a pharmaceutically ...
|
|
WO/2019/204523A1 |
Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and...
|
|
WO/2019/201297A1 |
The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmac...
|
|
WO/2019/196731A1 |
The present invention relates to the field of pesticides, and in particular to a substituted pyrazolyl pyrazole sulfonylurea compound or a pesticide acceptable salt or composition thereof and the use thereof. Said compound has a structur...
|
|
WO/2019/197682A1 |
The invention relates to pharmaceutical combination products comprising an HDAC inhibitor, e.g. (E)-N-(2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-be
nzenesulfonyl]-1H-pyrrol-3-yl}- acrylamide as well as salts and or solvents ther...
|
|
WO/2019/200382A1 |
Described herein are methods of treatment of cancer by administering a therapeutically effective amount of a cytotoxic alkylating agent and a nanoparticle formulation containing an inhibitor of poly (ADP-ribose) polymerase 1. Also disclo...
|
|
WO/2019/195751A1 |
Compounds of formula (I) wherein, R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as...
|
|
WO/2019/195777A1 |
Compounds of formula (I): wherein,R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as...
|
|
WO/2019/193540A1 |
The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein A, C, D, L2, L3, R1, R2, R3, R4, R 5, R6, z2, z4, z5, and z6 are as defined herein; or...
|
|
WO/2019/195207A1 |
The present disclosure relates to light-activated cannabinoid compounds and methods of use for photodynamic therapy and for treating cancer, inflammation, and infection.
|
|
WO/2019/194220A1 |
Provided are compounds represented by formula (1) or salts thereof, and a pest control agent, an insecticide or miticide, a nematicide, and an endoparasite control or eliminating agent, which contain, as an active ingredient, at least on...
|
|
WO/2019/193509A1 |
The present invention provides substituted pyrazole derivatives of formula (I), which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders...
|
|
WO/2019/186498A1 |
Fluoroalkenyl heterocyclic compounds having Formula (I) are described together with agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops.
|
|
WO/2019/186575A1 |
A pesticidal emulsifiable concentrate with widened spectrum of action on a plurality of pest insects and a plurality of fungal diseases includes a synergistically effective amount of an insecticide; a synergistically effective amount of ...
|
|
WO/2019/188456A1 |
Provided are: a compound having an anti-tumor activity and a cancer metastasis inhibiting activity; and an anti-tumor agent containing the compound as an active ingredient. A compound represented by formula (1) (wherein the ring A repres...
|
|
WO/2019/185033A1 |
The present invention provides an amide pyrazole compound used as a FGFR irreversible inhibitor, a preparation method therefor and uses thereof. The present invention specifically provides a compound of formula (I), a stereoisomer, a rac...
|
|
WO/2019/190999A1 |
Disclosed herein are methods of treating fibrotic disorders by administering compounds selective for CAPN1, CAPN2, and/or CAPN9 such that side effects, off pathway interactions, and/or toxicities are minimized. Such methods may, for exam...
|
|
WO/2019/190885A1 |
Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by...
|
|
WO/2019/183145A1 |
Disclosed are compounds of Formula (I) and (Ia) or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R4, R5, R6, and R7 are as described in any of the embodiments described ...
|
|
WO/2019/178480A1 |
In one aspect, the invention comprises compounds that bind and inhibit macrophage migration inhibitory factor. In another aspect, the invention provides methods of treating inflammatory disease, neurological disorders and cancer using th...
|
|
WO/2019/175152A1 |
The present invention refers to compounds of formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. The invention refers also to pharmaceutical compo...
|
